证券代码：920060 证券简称：万源通 公告编号：2025-063 昆山万源通电子科技股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 投资者关系活动类别 活动时间：2025 年 6 月 5 日 活动地点：线上会议 √特定对象调研 □业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 参会单位及人员：开源证券、民生证券、联储证券、中信证券、西部证券、 万和证券、山西证券、中金公司、浙商证券、华鑫证券、红塔证券、财信证券、 中银三星人寿、招商基金、东吴基金、浦银理财、乾惕投资、鹏山资产、乘是资 产、百勋资产、龙航资产、得桂私募基金、复通私募投资基金、泰石投资、尚诚 资产、前海世传国际投资、国晖投资、中航赛维投资、衍航研究与投资、星允投 资、同巨投资、青创伯乐投资、联创投资（排名不分先后） 上市公司接待人员：子公司副总经理：孙结忠先生； 公司董事会秘书：季佳佳女士。 三、 投资者关系活动主要内容 本次投资者关 ...

证券代码：920008 证券简称：成电光信 公告编号：2025-047 成都成电光信科技股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 √特定对象调研 二、 投资者关系活动情况 活动时间：2025 年 6 月 5 日 活动地点：成都成电光信科技股份有限公司 5 楼会议室 参会单位及人员：华源证券、开源证券、长江证券 上市公司接待人员：企业发展部部长李昱岐 三、 投资者关系活动主要内容 1、公司部分产品存在以暂定价结算，后续军方审价后再进行调整的情形， 请问公司按暂定价结算是否为行业常态？ 答：公司按暂定价结算属于行业特性，军方军品审价对象主要为总体单位 □业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 或总装单位，公司作为相关装备型号的配套供应商不属于军品审价的直接对 象，但部分重要配套产品可能被要求接受延伸审价，后续将根据军方及总体单 位要求积极配合审价工作。 2、公司产品毛利率稳定吗？ 答：公司已定型列 ...

证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 投资者关系活动记录表 编号：2025003 | 投资者关系活 | □特定对象调研 □分析师会议□媒体采访 | | | --- | --- | --- | | 动类别 | □业绩说明会□新闻发布会□路演活动 | | | | □现场参观□一对一沟通☑其他：电话会议 | | | | 国投证券 刘亚洲；圆石投资 李益峰；中银证券陈乐天、 | | | | 经煜甚；宏利基金 张帅、周笑雯；西部证券 吕晔、陆伏 | | | | 崴；中邮证券 陈峻；东方证券 陆佳晶；信达证券曹佳 | | | | 琳；进门财经 田自威；诺德基金 朱明睿；浦银安盛 | 徐 | | | 博；相聚资本 邓巧；建信养老金 李平祝；国盛证券 | 王 | | | 震；建信基金 张剑姝；青榕资管 唐明；易正朗投资乔 | | | 参与单位名称 | 越；广东民营投资王戈佳；淳厚基金张倬颖；招商基金 | 周 | | | 雨婷；翊安（上海）投资 赵汉辉；深圳尚诚资管 | 黄向 | | 及人员姓名 | 前；西南证券李根林；浦银安盛 张瑞；广东谢诺辰阳私募 | | | | 薛海涵；上海铭大实 ...

证券代码：300136 证券简称：信维通信 深圳市信维通信股份有限公司投资者关系活动记录表 编号：2025-04 | 投资者关 | □特定对象调研 □分析师会议 | | --- | --- | | 系活动类 | □媒体采访 业绩说明会 | | 别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （电话会议） | | 参与单位 | 参加深圳证券交易所"乘风远航・走向广阔新天地" 2024 年度集体 | | 名称及人 | 业绩说明会的投资者 | | 员姓名 | | | 时间 | 2025 年 06 月 06 日 | | 地点 | 深圳证券交易所 8 楼上市大厅 | | | 深交所"互动易"平台（http://irm.cninfo.com.cn） | | 上市公司 | | | 接待人员 | 董事会秘书：卢信 | | 姓名 | | | | 公司于 2025 年 06 月 06 日（星期五）下午 15：00—17：00 采 | | | 用视频直播与图文转播方式参加深交所"乘风远航・走向广阔新天 | | | 地" 2024 年度集体业绩说明会。本次交流主要内容如下： | | 投资者关 | 第一 ...

日化包装及家电、片材薄膜制品、医疗器械、3D 打印等领域。 新能源材料主要包括黑磷材料和电池粘结剂材料。黑磷材料 依托于控股子公司瑞丰玥能，于 2024 年完成百公斤装置的正常 运行，目前正在建设吨级中试生产线，预计于今年三季度投入运 行，继续推进黑磷的低成本产业化。电池粘结剂业务主要有 SBR 系列和其他系列负极粘结剂。于 2024 年实现量产推出数个牌号 产品并送样多家锂电池客户测试并实现小批量销售。当前，公司 正对标行业内最高水平的日本瑞翁/日本爱宇龙同类产品进行产 品品质提升实验，为进入高端应用市场做准备。 合成生物材料主要包括完成了聚乳酸、生物基丁二酸、右旋 糖酐等产品的中试，目前右旋糖酐产品已经得到市场认可并实现 小批量销售。公司计划进一步提高右旋糖酐的产能。 证券代码：300243 证券简称：瑞丰高材 山东瑞丰高分子材料股份有限公司 投资者关系活动记录表 | 投资者关系活动 | | √特定对象现场调研□分析师会议 | | --- | --- | --- | | 类别 | □媒体采访□业绩说明会 | | | | □新闻发布会□路演活动 | | | | □现场参观 | | | | □其他（请文字说明 ...

Group 1: Company Overview and Recent Performance - The company maintains high factory capacity utilization due to ongoing demand in the computing and automotive electronics markets [1] - The PCB business focuses on high-end products, primarily serving communication devices, data centers, and automotive electronics [1][2] Group 2: PCB Business Developments - The PCB business has seen increased demand for high-performance products driven by advancements in AI technology and high-speed networks [2] - The company is expanding its PCB production capacity through technological upgrades and new projects in various locations, including Shenzhen, Wuxi, Nantong, and Thailand [3] Group 3: Thailand Factory Investment - The total investment for the Thailand factory is 1.274 billion RMB, aimed at enhancing the company's capabilities in high-layer and HDI PCB technologies [4] Group 4: Packaging Substrate Business - The packaging substrate business has shown improvement in demand, particularly for storage products, compared to Q4 2024 [5] - The FC-BGA packaging substrate can produce products with up to 20 layers and has a minimum line width capability of 9/12μm [6][7] Group 5: Raw Material Price Impact - The prices of key raw materials, such as copper foil and gold salt, have increased in Q1 2025 compared to Q4 2024, affecting overall costs [7] Group 6: Electronic Assembly Business Strategy - The electronic assembly business focuses on communication, data centers, medical, and automotive electronics, aiming to provide integrated solutions and enhance customer loyalty [7]

重视在人工智能领域布局与投入，专注于前沿技术的研究与应用，将 机器视觉、大数据分析等人工智能技术与门店数字化场景相结合，以 提升客户门店经营效率和消费者的购物体验。公司正积极探索 AIoT 技术在更多场景中的应用，依托微软云服务平台，充分集成和应用微 软 Azure Open AI 所提供的大模型能力，开发面向零售场景的创新 AI 解决方案，运用生成式 AI 的文生图、交互响应等技术，在智能购物 助手、零售媒体网络（RMN）等方面进行了前瞻性的布局。作为微软 中国首家获得"Certified Software Designation for Retail AI"认证的合 作伙伴，公司已建立先发优势，未来将持续拓展 AI 技术在零售生态 的深度融合与战略应用。 问题二：电子价签全球市场的渗透率和未来市场空间如何？ 答：目前，全球电子价签整体市场渗透率仍属较低水平。其中，法国 渗透率最高，超过 40%（ePaper Insight 2025 年白皮书数据）。而 中国、美国、日本等市场的渗透率仍处于较低水平，具备较大的增量 空间。公司未来增长动力主要来自以下几个方面：首先，随着市场渗 透率的提升，增量市场有待行业共 ...

Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included representatives from multiple securities and funds [2] - The meeting took place at the company's headquarters on June 5, 2025 [2] Group 2: Purpose of the Meeting - The main objective was to understand the company's production and operational status [2] - The meeting involved discussions with the board secretary and investor relations management [2]

Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a 13.66% increase [2] - The net cash flow from operating activities was 714 million CNY, showing a significant growth of 35.39% [2] - The weighted average return on equity was 4.86%, an increase of 0.68 percentage points year-on-year [2] - The company held cash and cash equivalents of 11.062 billion CNY, with total assets amounting to 54.253 billion CNY [2] Pharmaceutical Business Growth - The pharmaceutical segment focused on "comprehensive management of pain in the injury field" as a strategic direction [3] - The segment enhanced its core products' efficacy in pain management through academic clinical research [4] - Key areas of focus included cardiovascular, respiratory, and pediatric medicine, with ongoing efforts to enrich the product pipeline [4] - Marketing strategies included the successful cultivation of proprietary sports IP, which contributed to brand youthfulness and increased product penetration [4] Oral Care Product Performance - In 2024, Yunnan Baiyao toothpaste maintained the top market share in the domestic oral care sector [5] - During major sales events like "618" and "Double Eleven," the brand consistently ranked first in online oral care sales [5] - Content marketing initiatives, such as the "Healthy Oral 123 Plan," significantly enhanced brand visibility, achieving over 6.43 billion exposures [6] Dividend Distribution - For the 2024 fiscal year, the company announced a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.164 billion CNY [7] - The total cash dividend for 2024, including special dividends, amounted to 23.98 CNY per 10 shares, representing 90.09% of the net profit attributable to shareholders [7] Nuclear Medicine R&D Progress - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024, with promising stability and safety results reported in November [9] - The company’s subsidiary received approval for clinical trials of INR102, an innovative drug for treating metastatic castration-resistant prostate cancer [9]

Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a growth of 13.66% [2] - The net cash flow from operating activities was 714 million CNY, an increase of 35.39% [2] - The weighted average return on equity was 4.86%, up by 0.68 percentage points year-on-year [2] - The company had a cash balance of 11.062 billion CNY and total assets of 54.253 billion CNY [2] Pharmaceutical Business Development - The pharmaceutical segment focused on establishing itself as the leading brand in pain management, launching a new pain management model [3] - Key areas of focus included cardiovascular, respiratory, and pediatric medicine, enhancing the product pipeline [4] - Clinical research in diabetes foot, skeletal pain, and other areas showed steady progress, expanding product application scenarios [4] - Marketing efforts included the successful promotion of the proprietary sports IP "Let's Go Play Ball," enhancing brand youthfulness [4] - The company optimized its operational platform, achieving significant quality and efficiency improvements throughout the year [4] Health Products Channel Development - The company has a well-established national sales team for health products, maintaining a leading market share in toothpaste [5] - Continuous optimization of the entire channel has strengthened traditional offline advantages while exploring new retail formats [6] - The channel advantages have significantly enhanced market competitiveness and laid a foundation for new product commercialization [6] Future Development Strategy - The company aims for growth through both "internal" and "external" collaborative development, optimizing its industrial portfolio [7] - "Internal" development focuses on enhancing efficiency and stability across the pharmaceutical, health, and distribution sectors [7] - "External" development involves strategic mergers and collaborations to overcome growth bottlenecks and build a sustainable industrial system [7] Dividend Distribution - For the 2024 fiscal year, the company plans to distribute a cash dividend of 11.85 CNY per 10 shares, with no stock dividends [8] - A special dividend of 12.13 CNY per 10 shares was completed in November 2024, totaling 2.164 billion CNY [8] - The total cash dividend for 2024 amounts to 23.98 CNY per 10 shares, totaling 4.279 billion CNY, which is 90.09% of the net profit attributable to shareholders [9]